Research programme: T-cell receptor directed T-cell therapies - Affini-T Therapeutics
Latest Information Update: 03 Aug 2022
At a glance
- Originator Affini-T Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 20 Jul 2022 Early research in Solid tumours in USA (Parenteral) (Affini-T Therapeutics pipeline, July 2022)